Immuron reports positive clinical study results in the fight against fatty liver disease
Dual-listed early-stage biotech company Immuron (ASX: IMC) has revealed keenly anticipated results for its phase 2 non-alcoholic steatohepatitis (NASH) clinical study. The primary objective of the study was to evaluate the safety and efficacy of IMM-124E.
https://smallcaps.com.au/immuron-positive-clinical-study-results-fight-fatty-liver-disease/
Filter by Year:
- Immuron’s shares surge on demonstrating proof of concept for liver drug candidate
- Immuron and US Department of Defense look to develop silver bullet for gastro infections
- Immuron's IMM-124E shows encouraging action in mid-stage NASH study; shares ahead 81%
- Blockbuster Results from IMC’s NASH Liver Therapy Trials
- Immuron reports positive clinical study results in the fight against fatty liver disease
- Results in: IMC’s lead drug reduces major factor in liver inflammation
- US Defense finishes latest research on Immuron’s Travelan®
This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.
